Cardiac Biomarkers in COVID-19: A Narrative Review

The diagnosis and risk stratification of coronavirus disease 2019 (COVID-19) is primarily based on discretionary use of laboratory resources. Several lines of evidence now attest that cardiovascular disease not only is a frequent complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but its pre-existence may increase the risk of morbidity, disability, and death in patients with COVID-19. To this end, routine assessment of biomarkers of cardiac injury (i.e., cardiac troponin I or T) and dysfunction (e.g., natriuretic peptides) has emerged as an almost essential practice in patients with moderate, severe, and critical COVID-19 illness. Therefore, this narrative review aims to provide an overview of cardiac involvement in patients with SARS-CoV-2 infection as well as the clinical background for including cardiac biomarkers within specific panels of laboratory tests for managing COVID-19 patients.

[1]  C. Specchia,et al.  The prognostic value of serial troponin measurements in patients admitted for COVID‐19 , 2021, ESC heart failure.

[2]  C. Dilber,et al.  Predictive value of cardiac markers in the prognosis of COVID-19 in children , 2021, The American Journal of Emergency Medicine.

[3]  A. Mangoni,et al.  B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression , 2021, Frontiers in Cardiovascular Medicine.

[4]  P. Martus,et al.  Impaired Myocardial Function Is Prognostic for Severe Respiratory Failure in the Course of COVID-19 Infection , 2021, Frontiers in Cardiovascular Medicine.

[5]  M. Zuin,et al.  Heart failure as a complication of COVID-19 infection: systematic review and meta-analysis , 2021, Acta cardiologica.

[6]  M. Vargas,et al.  B-Type Natriuretic Peptides and High-Sensitive Troponin I as COVID-19 Survival Factors: Which One Is the Best Performer? , 2021, Journal of clinical medicine.

[7]  S. Solomon,et al.  Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19 , 2021, Circulation.

[8]  B. Gersh,et al.  International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19 , 2021, Journal of the American College of Cardiology.

[9]  H. Katus,et al.  Interpretation of myocardial injury subtypes in COVID-19 disease per fourth version of Universal Definition of Myocardial Infarction , 2021, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  G. Lippi,et al.  Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness , 2021, Internal and Emergency Medicine.

[11]  C. Mueller,et al.  Cardiovascular biomarkers in COVID-19 , 2021, European heart journal. Acute cardiovascular care.

[12]  M. Barbagallo,et al.  Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19 , 2021, Laboratory medicine.

[13]  Arthur S Slutsky,et al.  Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections—A Systematic Review and Meta-Analysis , 2021, Critical care medicine.

[14]  C. Kaymaz,et al.  The prognostic role of cardiac troponin in hospitalized COVID-19 patients , 2021, Atherosclerosis.

[15]  S. Del Turco,et al.  A possible role for ST2 as prognostic biomarker for COVID-19 , 2021, Vascular Pharmacology.

[16]  A. Jaffe,et al.  Using high sensitivity cardiac troponin values in patients with SARS-CoV-2 infection (COVID-19): The Padova experience , 2021, Clinical Biochemistry.

[17]  R. Virmani,et al.  Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. , 2021, Circulation.

[18]  K. Hong,et al.  Prevalence and impact of cardiac injury on COVID‐19: A systematic review and meta‐analysis , 2020, Clinical cardiology.

[19]  Paloma Martin,et al.  Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction. , 2020, JAMA cardiology.

[20]  Andrew J. Layman,et al.  COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart , 2020, Circulation.

[21]  M. Diamond,et al.  SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis , 2020, bioRxiv.

[22]  G. Lippi,et al.  Coronavirus Disease 2019 (COVID-19)-Associated Coagulopathy , 2020, Mayo Clinic Proceedings.

[23]  J. Cheung,et al.  Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID‐19: Derivation and Validation of the HA2T2 COVID‐19 Mortality Risk Score , 2020, Journal of the American Heart Association.

[24]  G. Lippi,et al.  Cardiac Injury in COVID-19–Echoing Prognostication , 2020, Journal of the American College of Cardiology.

[25]  T. Omland,et al.  Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19 , 2020, Circulation.

[26]  G. Lippi,et al.  Exploring the association between extra-cardiac troponin elevations and risk of future mortality , 2020, Journal of medical biochemistry.

[27]  Jessica S. Brown,et al.  SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years - United States, February 12-July 31, 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[28]  R. Doshi,et al.  Prognostic Value of Elevated Cardiac Troponin I in Hospitalized Covid-19 Patients , 2020, The American Journal of Cardiology.

[29]  G. Lippi,et al.  Red Blood Cell Distribution Width (RDW) Predicts COVID-19 Severity: A Prospective, Observational Study from the Cincinnati SARS-CoV-2 Emergency Department Cohort , 2020, Diagnostics.

[30]  Jessica S. Brown,et al.  Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. , 2020, MMWR. Morbidity and mortality weekly report.

[31]  P. Kellman,et al.  COVID-19: Myocardial injury in survivors. , 2020, Circulation.

[32]  K. Ferdinand,et al.  Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: A meta‐regression and decision tree analysis , 2020, Journal of medical virology.

[33]  G. Lippi,et al.  Cardiac troponin elevation in patients with influenza virus infections , 2020, Biomedical journal.

[34]  G. Lippi,et al.  COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon , 2020, Annals of translational medicine.

[35]  G. Lippi,et al.  Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis , 2020, Current Problems in Cardiology.

[36]  Jocelyn Kaiser,et al.  A rampage through the body. , 2020, Science.

[37]  Giuseppe Lippi,et al.  Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm , 2020, Annals of translational medicine.

[38]  G. Lippi,et al.  Prognostic Value of Troponins in Patients With or Without Coronary Heart Disease: Is it Dependent on Structure and Biology? , 2019, Heart, lung & circulation.

[39]  G. Lippi,et al.  Predicting mortality with cardiac troponins: recent insights from meta-analyses , 2019, Diagnosis.

[40]  G. Lippi,et al.  Is one cardiac troponin better than the other? , 2019, Journal of Laboratory and Precision Medicine.

[41]  R. McKelvie,et al.  Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review , 2014, Heart Failure Reviews.